|
In clinical studies, the glucose-lowering effect on a molar basis of LANTUS®
basal insulin is approximately the same as NPH insulin.
In euglycemic clamp studies in healthy subjects or in patients with type 1 diabetes,
the onset of action of LANTUS® was slower than NPH insulin.
|
|
|
LANTUS® is the only 24-hour insulin approved exclusively for use once a day
1
*Between-patient variability (coefficient of variation): insulin glargine,
84% and NPH, 78%.
†Glucose utilization rate in mg/kg/min, determined as the amount of glucose
infused to maintain constant plasma glucose levels (hourly mean values); indicative
of insulin activity.
A double-blind, randomized, crossover, euglycemic clamp study involving 20 patients
with type 1 diabetes. From Lepore et al2
and LANTUS® Prescribing Information.1
The effect profile of LANTUS® basal insulin was relatively constant with no
pronounced peak and the duration of its effect was prolonged compared to NPH insulin.
- LANTUS® should be taken at the same time each day
IMPORTANT SAFETY INFORMATION FOR LANTUS®
LANTUS® is indicated for once-daily subcutaneous administration, at the same
time each day, for the treatment of adult and pediatric patients (6 years and older)
with type 1 diabetes mellitus or adult patients with type 2 diabetes mellitus who
require basal (long-acting) insulin for the control of hyperglycemia.
LANTUS® SoloSTAR® is a disposable prefilled insulin pen. Needles and the Lantus® SoloSTAR® pen must not be shared.
LANTUS® MUST NOT BE DILUTED OR MIXED WITH ANY OTHER INSULIN OR SOLUTION. If mixed
or diluted, the solution may become cloudy, and the onset of action/time to peak
effect may be altered in an unpredictable manner.
LANTUS® is contraindicated in patients hypersensitive to insulin glargine or
the excipients.
Hypoglycemia is the most common adverse effect of insulin, including LANTUS®.
As with all insulins, the timing of hypoglycemia may differ among various insulin
formulations. Glucose monitoring is recommended for all patients with diabetes.
Any change of insulin type and/or regimen should be made cautiously and only under
medical supervision. Concomitant oral antidiabetes treatment may need to be adjusted.
Other adverse events commonly associated with LANTUS® include the following:
lipodystrophy, skin reactions (such as injection-site reaction, pruritus, rash),
and allergic reactions.
In clinical studies in adult patients there was a higher incidence of treatment-emergent
injection-site pain (2.7% LANTUS® vs 0.7% NPH). The reports of pain at the injection
site were usually mild and did not result in discontinuation of therapy.
Please click here for full prescribing information.
